EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy
Author:
Affiliation:
1. Thoracic Oncology Unit, Nantes University Hospital, Nantes, France
2. INSERM, CRCINA, Nantes, France
3. Department of Biochemistry and Molecular Biology, Nantes University Hospital, Nantes, France
4. University of Nantes, France
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1757439
Reference47 articles.
1. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
4. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
5. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC;Emergency Medicine International;2022-06-10
2. Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study;Respiratory Research;2022-05-27
3. Commentary: Keeping the target painted for precision cancer therapy;The Journal of Thoracic and Cardiovascular Surgery;2021-08
4. Combined Treatment of Cinobufotalin and Gefitinib Exhibits Potent Efficacy against Lung Cancer;Evidence-Based Complementary and Alternative Medicine;2021-03-20
5. Chemotherapy resistance and YY1;YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3